New eye drug GB10 enters early human testing for wet AMD
NCT ID NCT07406438
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage trial tests a new drug called GB10, given as an eye injection, for people with wet age-related macular degeneration (AMD). The study will include 48 participants and aims to check safety and find the right dose. It is not yet recruiting and is too early to know if the drug works.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
GB10 (intravitreal injection)
What this could lead to
If successful, this could point toward a new treatment option for wet age-related macular degeneration that may reduce the need for frequent eye injections.
What could go wrong
This is a very early Phase 1 trial with only 48 participants, focused on safety and dosing. It is too small and early to know if GB10 will work or be safe long-term.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Beijing Tongren Hospital, Capital Medical University
Beijing, Beijing Municipality, 100730, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Contact
-
Henan Provincial Eye Hospital
Zhengzhou, Henan, 450015, China
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Nanchang University Second Affiliated Hospital
Nanchang, Jiangxi, 330006, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Sir Run Run Shaw Hospital (SRRSH), affiliated with Zhejiang University School of Medicine
Hangzhou, Zhejiang, 310016, China
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
The Affiliated Hospital of Guizhou Medical University
Guiyang, Guizhou, 550004, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Zhejiang Provincial People's Hospital
Hangzhou, Zhejiang, 310014, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact